A Phase 4 interventional study of Maraviroc and Placebo in HIV Coinfection, sponsored by ViiV Healthcare. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-06.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.
Among the 44 studies testing maraviroc in HIV Infections, this one is the 10th largest by enrollment, is one of 3 that started in 2011, is one of 15 in phase 4, and was the 34th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 9 · Phase 4 15
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 36 across the 44 interventional studies. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 81st largest by enrollment of the 210 interventional ones that give a count, is one of 3 that started in 2011, is one of 18 in phase 4, and was the 145th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing maraviroc in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc
Drug: Placebo
150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
Also known as: Selzentry, Celsentri
150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48
Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 48 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.
Time frame: 48 weeks
Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144
Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 96 and Week 144 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.
Time frame: Week 96 and 144
Time to Development of Grade 3 and Grade 4 ALT Abnormalities
Time taken in days to development of Grade 3 and Grade 4 ALT abnormalities defined as \>5x ULN for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, at Week 144.
Time frame: 144 weeks
Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Associated With a Change From Baseline ALT >100 IU/L
Percentage of participants who had Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.
Time frame: 144 weeks
Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L
Time to development of Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.
Time frame: 144 weeks
Number of Participants With Hy's Law Abnormalities Through Week 144
Hy's law was defined as a total bilirubin \>2x ULN with a simultaneous ALT or aspartate transaminase (AST)\>3x ULN, excluding participants with an alkaline phosphatase\>3x ULN
Time frame: 144 weeks
Percentage of Participants With Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Concentration <40 Copies/mL at Week 48, 96 and 144
The Food and Drug Administration (FDA's) snapshot algorithm was used to derive the efficacy endpoint of the proportion of participants with HIV-1 RNA \<40 copies/mL at Week 48. This algorithm included the missing data imputation method and used the plasma HIV-1 RNA concentration in the visit window only, followed the "virology-first principle" and considered a participant who had a missing plasma HIV-1 RNA concentration, or switched to a prohibited background anti-retroviral regimen or discontinues from the study or study drug as a failure (MSDF).
Time frame: Week 48, 96 and 144
Mean Change From Baseline in CD4+ and CD8+ Cell Counts at Week 48, 96 and 144
Immunologic response (magnitude of change in CD4+ and CD8+ cell counts from baseline) was measured. Baseline value for CD4 and CD8 is defined as the pre-dose measurement taken at Day 1 visit.
Time frame: Week 48, 96 and 144
Mean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144
Plasma samples were used to determine markers of immune activation namely CD38 expression on CD4 and CD8 cells.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Markers of Immune Activation: C-reactive Protein (CRP) - Week 48, 96 and 144.
Plasma samples were used to determine markers of immune activation namely CRP.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Markers of Immune Activation: D Dimer - Week 48, 96 and 144
Plasma samples were used to determine markers of immune activation namely D-Dimer.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Markers of Immune Activation: Transforming Growth Factor-beta (TGF Beta) - Week 48, 96 and 144
Plasma samples were used to determine markers of immune activation namely TGF beta.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Log10 Plasma Hepatitis C Virus (HCV) RNA at Week 48, 96 and 144
Plasma samples were used to determine HCV RNA using the Roche COBAS Ampliprep/COBAS HCV Taqman assay, RUO version (LOD=15 IU/mL).Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Plasma Hepatitis B Virus (HBV) DNA at Week 48, 96 and 144
Plasma samples were used to determine HBV DNA using the Roche COBAS Taqman HBV assay. Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in Enhanced Liver Fibrosis (ELF) Test at Week 48, 96 and 144
The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on an ADVIA Centaur XP and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.
Time frame: 48, 96 and 144 weeks
Mean Change From Baseline in the Hepatic Elastography (FibroscanTM) at Week 48, 96 and 144
Participants had transient hepatic elastography using FibroScan technology. It rapidly and non invasively measures hepatic tissue stiffness. Through a probe, a low frequency vibration of low amplitude is transmitted to the liver. The velocity of the wave that is generated during the procedure correlates directly with tissue stiffness as it passes through the liver; the harder or stiffer the liver, the faster the shear wave propagates. Results are reported in kilopascals (kPa). A negative change in the fibroscan values (i.e. decrease in liver stiffness) correlates with a decrease in fibrosis and thus improved outcome.
Time frame: 48, 96 and 144 weeks
Absolute Fibrosis Score (Ishak) in Liver Biopsy Samples at Baseline and at Week 144
Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.
Time frame: Baseline and Week 144
Change From Baseline in Fibrosis Score (Ishak) in Liver Biopsy Samples at Week 144
Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.
Time frame: Week 144
Percentage of Participants Who Were Hospitalized Due to Hepatic Disease Through Week 144
Healthcare resource utilization data was collected using the Healthcare Resource Utilization Questionnaire at all study visits except Screening and Baseline. Other components of healthcare resource utilization, including length of hospital stay, type of ward, associated investigative and therapeutic procedures and concomitant medications were captured from primary and secondary data sources.
Time frame: 144 Weeks
Summary of Estimated Maraviroc PK Parameters
Week 4 and Week 48 clinic visits were scheduled such that a trough sample may be taken within a time window of 8-16 hours after the previous dose (Ctrough). Blood samples (4mL) were collected from all participants at the Week 4 and 48 visits.
Time frame: Week 48
Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48
The relationship between change from baseline in liver fibrosis biomarkers (AST, ALT, ALK, BIL, ELF and FSCN) versus MVC Cavg was analyzed using Bayesian methods. P-values were assessed for significance in the relationship between liver fibrosis biomarkers and MVC Cavg. P-value \<0.05 was regarded as significantly related.
Time frame: Week 48
In this study, 138 participants were randomized, of which 137 participants received the study drug. Participants were randomized at 37 sites in 9 countries. Five sites received drug and screened subjects but did not randomize any subjects; 2 sites received drug but did not screen any subjects.
| Milestone | Maraviroc | Placebo |
|---|---|---|
| Started | 70 | 67 |
| Randomized and not treated | 0 | 1 |
| Completed | 50 | 45 |
| Not completed | 20 | 22 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Non-compliance with study treatment | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Withdrew: Does not meet entrance criteria | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Non-compliance due to alcohol intake | 0 | 1 |
| Withdrew: Required prohibited medication | 2 | 0 |
| Withdrew: Non-compliance with study procedures | 1 | 0 |
| Withdrew: By investigator in subject's interest | 0 | 1 |
Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 48 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.
| Percentage of participants | Maraviroc | Placebo |
|---|---|---|
| Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48 | 1.4 | 1.5 |
Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 96 and Week 144 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.
| Percentage of participants | Maraviroc | Placebo |
|---|---|---|
| at Week 96 | 1.4 | 3.0 |
| at Week 144 | 2.9 | 4.5 |
Time taken in days to development of Grade 3 and Grade 4 ALT abnormalities defined as \>5x ULN for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, at Week 144.
| Days | Maraviroc | Placebo |
|---|---|---|
| Time to Development of Grade 3 and Grade 4 ALT Abnormalities | NA (NA to NA) | NA (NA to NA) |
Percentage of participants who had Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.
| Percentage of participants | Maraviroc | Placebo |
|---|---|---|
| Grade 3 | 2.8 | 4.4 |
| Grade 4 | 1.4 | 0.0 |
Time to development of Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.
| Days | Maraviroc | Placebo |
|---|---|---|
| Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L | NA (NA to NA) | NA (NA to NA) |
Hy's law was defined as a total bilirubin \>2x ULN with a simultaneous ALT or aspartate transaminase (AST)\>3x ULN, excluding participants with an alkaline phosphatase\>3x ULN
| participants | Maraviroc | Placebo |
|---|---|---|
| Number of Participants With Hy's Law Abnormalities Through Week 144 | 0 | 0 |
The Food and Drug Administration (FDA's) snapshot algorithm was used to derive the efficacy endpoint of the proportion of participants with HIV-1 RNA \<40 copies/mL at Week 48. This algorithm included the missing data imputation method and used the plasma HIV-1 RNA concentration in the visit window only, followed the "virology-first principle" and considered a participant who had a missing plasma HIV-1 RNA concentration, or switched to a prohibited background anti-retroviral regimen or discontinues from the study or study drug as a failure (MSDF).
| Percentage of participants | Maraviroc | Placebo |
|---|---|---|
| Week 48 | 77.1 | 79.1 |
| Week 96 | 67.1 | 70.1 |
| Week 144 | 58.6 | 67.2 |
Immunologic response (magnitude of change in CD4+ and CD8+ cell counts from baseline) was measured. Baseline value for CD4 and CD8 is defined as the pre-dose measurement taken at Day 1 visit.
| Cells/µL | Maraviroc | Placebo |
|---|---|---|
| CD4+ (week 48, n=69, 67) | 3.1 ± 142.58 | 42.0 ± 166.35 |
| CD8+ (week 48, n=69, 67) | 7.8 ± 229.53 | 28.9 ± 293.18 |
| CD4+ (week 96, n=69, 67) | 5.1 ± 146.64 | 49.7 ± 177.18 |
| CD8+ (week 96, n=69, 67) | -2.7 ± 228.92 | 62.6 ± 376.67 |
| CD4+ (week 144, n=69, 67) | 17.2 ± 184.86 | 41.7 ± 200.00 |
| CD8+ (week 144, n=69, 67) | 12.6 ± 293.82 | 44.1 ± 387.61 |
Plasma samples were used to determine markers of immune activation namely CD38 expression on CD4 and CD8 cells.
| cell/mm³ | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n=69, 67) | -12.2 ± 129.82 | 43.0 ± 135.71 |
| Week 96 (n=69, 67) | 5.4 ± 134.64 | 47.4 ± 186.74 |
| Week 144(n=69, 67) | 23.4 ± 169.50 | 50.7 ± 219.95 |
Plasma samples were used to determine markers of immune activation namely CRP.
| mg/dL | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n=70, 67) | 0.4 ± 8.18 | 3.1 ± 26.66 |
| Week 96 (n=70, 67) | 0.0 ± 5.16 | -0.7 ± 3.32 |
| Week 144 (n=70, 67) | 0.6 ± 7.99 | -0.3 ± 5.28 |
Plasma samples were used to determine markers of immune activation namely D-Dimer.
| ng/dL | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 68, 65) | -101.1 ± 753.24 | -20.4 ± 215.62 |
| Week 96 (n= 68, 65) | -88.1 ± 740.14 | -23.1 ± 201.55 |
| Week 144 (n= 68, 65) | -97.4 ± 768.98 | 9.8 ± 358.07 |
Plasma samples were used to determine markers of immune activation namely TGF beta.
| ng/L | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 67, 66) | 64.1 ± 4857.31 | -165.0 ± 2584.89 |
| Week 96 (n= 67, 66) | -227.5 ± 4417.59 | -296.5 ± 2200.97 |
| Week 144 (n= 67, 66) | 792.0 ± 6772.41 | 1275.4 ± 5044.79 |
Plasma samples were used to determine HCV RNA using the Roche COBAS Ampliprep/COBAS HCV Taqman assay, RUO version (LOD=15 IU/mL).Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.
| Log10 values | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 45, 45) | -3.2 ± 0.60 | -3.2 ± 0.68 |
| Week 96 (n= 45, 45) | -3.2 ± 0.50 | -3.4 ± 0.81 |
| Week 144 (n= 45, 45) | -3.1 ± 0.57 | -3.3 ± 0.72 |
Plasma samples were used to determine HBV DNA using the Roche COBAS Taqman HBV assay. Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.
| Log10 values | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 15, 10) | -2.6 ± 1.55 | -3.0 ± 0.11 |
| Week 96 (n= 15, 14) | -3.3 ± 0.94 | -3.0 ± 0.00 |
| Week 144 (n= 15, 15) | -3.4 ± 0.96 | -3.0 ± 0.00 |
The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on an ADVIA Centaur XP and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.
| ELF score | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 70, 67) | 0.2 ± 0.70 | 0.1 ± 0.71 |
| Week 96 (n= 70, 67) | 0.4 ± 0.73 | 0.4 ± 0.58 |
| Week 144 (n= 70, 67) | 0.4 ± 0.72 | 0.4 ± 0.69 |
Participants had transient hepatic elastography using FibroScan technology. It rapidly and non invasively measures hepatic tissue stiffness. Through a probe, a low frequency vibration of low amplitude is transmitted to the liver. The velocity of the wave that is generated during the procedure correlates directly with tissue stiffness as it passes through the liver; the harder or stiffer the liver, the faster the shear wave propagates. Results are reported in kilopascals (kPa). A negative change in the fibroscan values (i.e. decrease in liver stiffness) correlates with a decrease in fibrosis and thus improved outcome.
| kPa | Maraviroc | Placebo |
|---|---|---|
| Week 48 (n= 25, 28) | -1.3 ± 2.41 | 0.4 ± 5.71 |
| Week 96 (n= 25, 28) | -0.8 ± 2.95 | 0.4 ± 5.70 |
| Week 144 (n= 25, 28) | -1.7 ± 2.45 | -0.3 ± 4.39 |
Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.
| Numerical score | Maraviroc | Placebo |
|---|---|---|
| Absolute Values at Baseline | 2.6 ± 2.30 | 1.5 ± 3.0 |
| Absolute Values at Post-dose (or Week 144) | 2.2 ± 1.30 | 1.5 ± 3.0 |
Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.
| Numerical score | Maraviroc | Placebo |
|---|---|---|
| Absolute Values at Baseline | 3 (0 to 6) | 0 (0 to 6) |
| Absolute Values at Post-dose (or Week 144) | 2 (1 to 4) | 0 (0 to 6) |
| Change from baseline in fibrosis score at Week 144 | 0.0 (-2.0 to 1.0) | 0.0 (0.0 to 0.0) |
Healthcare resource utilization data was collected using the Healthcare Resource Utilization Questionnaire at all study visits except Screening and Baseline. Other components of healthcare resource utilization, including length of hospital stay, type of ward, associated investigative and therapeutic procedures and concomitant medications were captured from primary and secondary data sources.
| Percentage of participants | Maraviroc | Placebo |
|---|---|---|
| Not Hospitalized | 71.4 | 70.1 |
| Hospitalized due to Hepatic Disease at least once | 10.0 | 5.0 |
| Hospitalized, but not due to Hepatic Disease | 95.0 | 95.0 |
Week 4 and Week 48 clinic visits were scheduled such that a trough sample may be taken within a time window of 8-16 hours after the previous dose (Ctrough). Blood samples (4mL) were collected from all participants at the Week 4 and 48 visits.
| ng/mL | Maraviroc 150 mg | Maraviroc 300 mg | Maraviroc 600 mg |
|---|---|---|---|
| Cavg | 262 (35 to 455) | 166 (72 to 187) | 309 (79 to 656) |
| Cmax | 496 (47 to 768) | 258 (162 to 528) | 915 (133 to 1734) |
| Cmin | 127.2 (21.6 to 280.5) | 61.3 (19.5 to 112.9) | 69.2 (17.3 to 250.9) |
The relationship between change from baseline in liver fibrosis biomarkers (AST, ALT, ALK, BIL, ELF and FSCN) versus MVC Cavg was analyzed using Bayesian methods. P-values were assessed for significance in the relationship between liver fibrosis biomarkers and MVC Cavg. P-value \<0.05 was regarded as significantly related.
| p-value | Aspartate Transaminase (AST) | Alanine Transaminase (ALT) | Bilirubin (BIL) | Enhanced Liver Fibrosis (ELF) | Fibroscan (FSCN) | Alkaline Phosphatase (ALK) |
|---|---|---|---|---|---|---|
| Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48 | 0.892 | 0.440 | 0.766 | 0.795 | 0.087 | 0.071 |
Collected over From the date of signing informed consent form up to 30 days after last dose of the study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc | — | 22/70 (31.4%) | 63/70 (90%) |
| Placebo | — | 19/67 (28.4%) | 62/67 (92.5%) |
| Event | Maraviroc | Placebo |
|---|---|---|
| BronchopneumoniaInfections and infestations | 3/70 | 0/67 |
| SyncopeNervous system disorders | 2/70 | 0/67 |
| Angina pectorisCardiac disorders | 0/70 | 1/67 |
| Myocardial infarctionCardiac disorders | 0/70 | 1/67 |
| Supraventricular tachycardiaCardiac disorders | 0/70 | 1/67 |
| Adrenal insufficiencyEndocrine disorders | 0/70 | 1/67 |
| CushingoidEndocrine disorders | 0/70 | 1/67 |
| GastritisGastrointestinal disorders | 0/70 | 1/67 |
| Chest painGeneral disorders | 0/70 | 1/67 |
| CellulitisInfections and infestations | 0/70 | 1/67 |
| Event | Maraviroc | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/70 | 12/67 |
| Upper respiratory tract infectionInfections and infestations | 11/70 | 11/67 |
| Back painMusculoskeletal and connective tissue disorders | 4/70 | 10/67 |
| BronchitisInfections and infestations | 10/70 | 7/67 |
| NauseaGastrointestinal disorders | 7/70 | 9/67 |
| NasopharyngitisInfections and infestations | 9/70 | 6/67 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/70 | 2/67 |
| SyphilisInfections and infestations | 3/70 | 8/67 |
| ToothacheGastrointestinal disorders | 1/70 | 7/67 |
| VomitingGastrointestinal disorders | 5/70 | 7/67 |
A participant was included in the FAS if the participant had taken at least one dose of study drug.
| Age, Customized(Participants) | Maraviroc | Placebo | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18-44 years | 26 | 20 | 46 |
| 45-64 years | 42 | 47 | 89 |
| ≥65 years | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Maraviroc | Placebo | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 60 | 57 | 117 |
Ran from May 2011 to primary completion in Apr 2013, 23 months.
Results were first posted in Nov 2014, 1 year 6 months after primary completion.
Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc